secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001193125-23-229101
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Appoints Charles S. Ryan as President; subsidiary issues up to $1M promissory note to EryDel S.p.A.
--------------------------------------------------------------------------------

- Promissory note of up to $1.0M to EryDel S.p.A. in two tranches: $500k at 5.07% per annum; second $500k at AFR.
- Maturity July 1, 2024; obligations discharged upon closing of Stock Purchase Agreement or termination in certain circumstances.
- Charles S. Ryan, Ph.D. appointed President, effective Sept 1, 2023; previously President/CEO of Travecta Therapeutics, CEO of Neurotrope.
- Compensation: $500k base salary, up to 40% bonus, option for 545,000 shares vesting over 4 years.
- Severance: 12-month salary on qualifying termination; 18-month salary if change of control, plus equity acceleration and health benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/d437171d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-229101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer